Hyperphosphatemia is a well-known feature of advanced chronic kidney disease (CKD) and
a major risk factor for cardiovascular events in patients with CKD, inducing calcium …

There is an intimate association between mineral and bone disorders in chronic kidney
disease (CKD) and the extensive burden of cardiovascular disease (CVD) in this population …

The colossal progress in understanding of vitamin D and phosphate metabolism introduces
new perspectives in chronic kidney disease (CKD) therapy. Increasing demand for …

The kidney is a key player in phosphate balance. Inappropriate renal phosphate transport
may alter serum phosphate concentration and bone mineralization, and increase the risk of …

Chronic kidney disease (CKD) affects approximately 500 million people worldwide and is
increasingly common in both industrialized and emerging countries. Although the …

The kidneys excrete excess dietary phosphate, and patients with chronic kidney disease
may suffer from phosphate overload and hyperphosphatemia. In chronic kidney disease …

Efforts to control phosphate retention/hyperphosphatemia in CKD have focused on limiting
gastrointestinal phosphate absorption through dietary and pharmacologic means. Suffice it …

Growing interest has been focused on the pathogenesis of chronic kidney disease-mineral
and bone disorder (CKD-MBD), which is not restricted to those with end-stage CKD and …

The discovery of fibroblast growth factor 23 (FGF23), a novel bone‐derived hormone that
inhibits phosphate reabsorption and calcitriol production by the kidney, has uncovered …

Background: The perturbation of phosphate homeostasis portends unfavorable outcomes in
chronic kidney disease (CKD). However, the absence of randomized clinical trials (RCT) …